A Patient-Derived Xenograft Model for Venous Malformation.
Animals
Cell Proliferation
/ drug effects
Class I Phosphatidylinositol 3-Kinases
/ genetics
Collagenases
/ metabolism
Disease Models, Animal
Endothelial Cells
/ drug effects
Fibronectins
/ pharmacology
Heterografts
Humans
Injections, Subcutaneous
Male
Mice, Nude
Sclerotherapy
Vascular Malformations
/ genetics
Veins
/ abnormalities
Journal
Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
31
10
2020
Statut:
epublish
Résumé
Venous malformation (VM) is a vascular anomaly that arises from impaired development of the venous network resulting in dilated and often dysfunctional veins. The purpose of this article is to carefully describe the establishment of a murine xenograft model that mimics human VM and is able to reflect patient heterogeneity. Hyper-activating non-inherited (somatic) TEK (TIE2) and PIK3CA mutations in endothelial cells (EC) have been identified as the main drivers of pathological vessel enlargement in VM. The following protocol describes the isolation, purification and expansion of patient-derived EC expressing mutant TIE2 and/or PIK3CA. These EC are injected subcutaneously into the back of immunodeficient athymic mice to generate ectatic vascular channels. Lesions generated with TIE2 or PIK3CA-mutant EC are visibly vascularized within 7‒9 days of injection and recapitulate histopathological features of VM patient tissue. This VM xenograft model provides a reliable platform to investigate the cellular and molecular mechanisms driving VM formation and expansion. In addition, this model will be instrumental for translational studies testing the efficacy of novel drug candidates in preventing the abnormal vessel enlargement seen in human VM.
Identifiants
pubmed: 32597867
doi: 10.3791/61501
pmc: PMC7457366
mid: NIHMS1618387
doi:
Substances chimiques
Fibronectins
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Collagenases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL117952
Pays : United States
Références
Clin Plast Surg. 2005 Jan;32(1):99-116, ix
pubmed: 15636768
Sci Transl Med. 2016 Mar 30;8(332):332ra43
pubmed: 27030595
Angiogenesis. 2020 Aug;23(3):425-442
pubmed: 32350708
J Tissue Eng Regen Med. 2015 May;9(5):632-6
pubmed: 23955835
Ann Vasc Surg. 2012 Jul;26(5):665-73
pubmed: 22664281
Nat Genet. 2009 Jan;41(1):118-24
pubmed: 19079259
Blood. 2009 Jul 9;114(2):237-47
pubmed: 19339693
J Clin Invest. 2015 Sep;125(9):3491-504
pubmed: 26258417
Am J Hum Genet. 2015 Dec 3;97(6):914-21
pubmed: 26637981
Phlebology. 2010 Oct;25(5):224-35
pubmed: 20870869
Angiogenesis. 2018 Nov;21(4):725-735
pubmed: 29786783
Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):496-512
pubmed: 30626204
J Tissue Eng Regen Med. 2011 Apr;5(4):e74-86
pubmed: 21413157
Cells. 2019 Aug 13;8(8):
pubmed: 31412684
Angiogenesis. 2018 Aug;21(3):425-532
pubmed: 29766399
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
Sci Transl Med. 2016 Mar 30;8(332):332ra42
pubmed: 27030594